Deptartment of Hematology, Oncology, and Tumor Immunology Charité; University Medicine Berlin; Campus Berlin-Buch, Campus Benjamin Franklin and Campus Virchow-Klinikum; Berlin, Germany ; Max Delbrück Center for Molecular Medicine; Berlin, Germany.
Oncoimmunology. 2012 Dec 1;1(9):1537-1545. doi: 10.4161/onci.22563.
DNA vaccines are potential tools for the induction of immune responses against both infectious disease and cancer. The dermal application of DNA vaccines is of particular interest since the epidermal and dermal layers of the skin are characterized by an abundance of antigen-presenting cells (APCs). The aim of our study was to compare tumor protection as obtained by two different methods of intradermal DNA delivery (gene gun and jet injector) in a well-established HER2/neu mouse tumor model. BALB/c mice were immunized twice with a HER2/neu-coding plasmid by gene gun or jet injector. Mice were then subcutaneously challenged with HER2/neu(+) syngeneic D2F2/E2 tumor cells. Protection against subsequent challenges with tumor cells as well as humoral and T-cell immune responses induced by the vaccine were monitored. Gene gun immunization was far superior to jet injector both in terms of tumor protection and induction of HER2/neu-specific immune responses. After gene gun immunization, 60% of the mice remained tumor-free until day 140 as compared with 25% after jet injector immunization. Furthermore, gene gun vaccination was able to induce both a strong T(H)1-polarized T-cell response with detectable cytotoxic T-lymphocyte (CTL) activity and a humoral immune response against HER2/neu, whereas the jet injector was not. Although the disadvantages that were associated with the use of the jet injector in our model may be overcome with methodological modifications and/or in larger animals, which exhibit a thicker skin and/or subcutaneous muscle tissue, we conclude that gene gun delivery constitutes the method of choice for intradermal DNA delivery in preclinical mouse models and possibly also for the clinical development of DNA-based vaccines.
DNA 疫苗是诱导针对传染病和癌症的免疫反应的潜在工具。由于皮肤的表皮和真皮层具有丰富的抗原呈递细胞 (APC),因此 DNA 疫苗的皮内应用尤其受到关注。我们的研究目的是比较两种不同的皮内 DNA 传递方法(基因枪和喷射注射器)在既定的 HER2/neu 小鼠肿瘤模型中获得的肿瘤保护作用。BALB/c 小鼠通过基因枪或喷射注射器两次免疫 HER2/neu 编码质粒。然后,将小鼠用 HER2/neu(+)同源 D2F2/E2 肿瘤细胞皮下攻击。监测疫苗诱导的针对随后肿瘤细胞的攻击的保护作用以及体液和 T 细胞免疫反应。在肿瘤保护和诱导 HER2/neu 特异性免疫反应方面,基因枪免疫明显优于喷射注射器。与喷射注射器免疫后 25%的小鼠在第 140 天仍未发生肿瘤相比,基因枪免疫后 60%的小鼠未发生肿瘤。此外,基因枪疫苗接种能够诱导可检测到细胞毒性 T 淋巴细胞 (CTL)活性的强烈 Th1 极化 T 细胞反应和针对 HER2/neu 的体液免疫反应,而喷射注射器则不能。尽管我们模型中使用喷射注射器存在一些缺点,但通过方法学改进和/或在皮肤较厚和/或皮下肌肉组织较大的动物中可能会克服这些缺点,我们得出结论,基因枪传递是临床前小鼠模型中皮内 DNA 传递的首选方法,并且可能也是 DNA 疫苗临床开发的首选方法。